Effect of Sn Atom on Poly(Ｌ-lactic acid) Pyrolysis

Tin 2-ethylhexanoate is an indispensable component of commercially available poly(L-lactic acid) (PLLA). However, the thermal degradation kinetics of PLLA containing Sn have not yet clearly been established; in particular, whether the degradation mechanism is a 1st-order or a random reaction. To clarify the effects of residual Sn on PLLA pyrolysis, PLLA samples with different Sn contents from 20 to 607 ppm were prepared and subjected to pyrolysis analysed with pyrolysis-gas chromatography/mass spectroscopy (Py-GC/MS) and thermogravimetry (TG). The pyrolysis of PLLA Sn-607 (Sn content: 607 ppm) with Py-GC/MS in the temperature range of 40–400 °C selectively produced lactides. In contrast, the pyrolysis of PLLA Sn-20 (Sn content: 20 ppm) was accompanied by the production of cyclic oligomers. The dynamic pyrolysis of PLLA-Sn samples by TG clearly indicated that with an increase in Sn content there was a shift to a lower degradation temperature range and a decrease in activation energy Ea. The kinetic analysis of the dynamic pyrolysis data indicates that the Sn-catalyzed pyrolysis starts through a random degradation behaviour and then shifts to a zero-order weight loss as the main process. Three reactions were put forward as being possible mechanisms of the zero-order weight loss; one being an unzipping reaction accompanying a random transesterification, the other two being the Sn-catalyzed pseudo-selective and selective lactide elimination reactions from random positions on a polymer chain. The kinetic parameter values obtained could be adequately explained for each degradation process

Pyrolysis Kinetics of Poly(L-lactide) with Carboxyl and Calcium Salt End Structures

To clarify the pyrolysis mechanism of poly(L-lactide), which has been reported as complex, the thermal decomposition of carboxyl type and calcium ion end capped PLLA (PLLA-H and PLLA-Ca, respectively) was investigated by means of thermogravimetric analysis (TG), and pyrolysis-gas chromatography-mass spectrometry (Py-GC-MS). The TG data revealed that PLLA-Ca has a lower pyrolysis temperature (220~360°C) than that of carboxyl type PLLA-H (280~370°C). The apparent activation energy of the decomposition reaction was estimated from TG curves at different heating rates by plural methods to be 176 and 98 kJ mol-1 for PLLA-H and PLLA-Ca, respectively. Further kinetic studies indicated that PLLA-H degraded mainly through a random reaction with a pre-exponential factor A=2.0×1012 s-1, whereas PLLA-Ca degraded by way of a 1st-order reaction with A=8.4×105 s-1. Pyrolysis products of PLLA-H were composed of lactides and other cyclic oligomers, while the degradation products of PLLA-Ca were principally lactides. The main reaction pathway for PLLA-H pyrolysis was regarded as the random transesterification, whereas for PLLA-Ca pyrolysis the unzipping depolymerization process was dominant

PCR-based DGGE and FISH analysis of methanogens in an anaerobic closed digester tank for treating palm oil mill effluent

16S ribosomal RNA (rRNA)-targeted fluorescent in situ hybridization combined with polymerase chain reaction (PCR)-cloning, light microscopy using Gram stains, scanning electron microscopy and denatured gradient gel electrophoresis were used to reveal the distribution of methanogens within an anaerobic closed digester tank fed with palm oil mill effluent. For specific detection of methanogens, 16S rRNA-cloning analysis was conducted followed by restriction fragment length polymorphism (RFLP) for presumptive identification of methanogens. To cover the drawbacks of the PCR-cloning study, the organization of the microorganisms was visualized in the activated sludge sample by using fluorescent oligonucleotide probes specific to several different methanogens, and a probe for bacteria. In situ hybridization with methanogens and bacterial probes and denatured gradient gel electrophoresis within activated sludge clearly confirmed the presence of Methanosaeta sp. and Methanosarcina sp. cells. Methanosaeta concilii was found to be the dominant species in the bioreactor. These results revealed the presence of possibly new strain of Methanosaeta in the bioreactor for treating palm oil mill effluent called Methanosaeta concilii SamaliEB (Gene bank accession number: EU580025). In addition, fluorescent hybridization pictured the close association between the methanogens and bacteria and that the number of methanogens was greater than the number of bacteria

Bone marrow-derived vasculogenesis leads to scarless regeneration in deep wounds with periosteal defects

Deep skin wounds with periosteal defects, frequently caused by traffic accidents or radical dissection, are refractory. Transplant surgery is frequently performed, but patients are subjected to stress for long operation periods, the sacrifice of donor regions, or several complications, such as flap necrosis or intractable ulcers. Even if the defects are covered, a scar composed of fibrous tissue remains in the body, which can cause itching, dysesthesia, or repeated ulcers because of the lack of distribution of peripheral nerves or hair follicles. Thus, treatments with the aim of regenerating lost tissue for deep wounds with periosteal defects are needed. Here, we show that the use of gelatin sponges (GS), which have been used as haemostatic materials in clinical practice, allowed the regeneration of heterogeneous tissues, including periosteum, skin, and skin appendages, when used as scaffolds in deep wounds with periosteal defects in rats. Bone marrow transplantation in rats revealed the mechanism by which the microenvironment provided by GS enabled bone marrow-derived cells (BMDCs) to form a vascular niche, followed by regeneration of the periosteum, skin, or skin appendages such as hair follicles by local cells. Our findings demonstrated that vascular niche formation provided by BMDCs is crucial for heterogeneous tissue regeneration

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362